Developing Positive Functional Modulators (PFMs) to restore and enhance membrane protein function and address the underlying cause of serious diseases.
With a $100M series A co-led by Atlas Venture, Omega Funds, Forbion and Longwood Fund, Rectify is developing personalized therapies to restore ABC transporter function in multiple organs. An Emerging Company Profile by BioCentury's @DanielleGolovinbuff.ly/3C1qPuG